

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
26 May 2005 (26.05.2005)

PCT

(10) International Publication Number  
**WO 2005/047266 A1**

(51) International Patent Classification<sup>7</sup>: **C07D 233/58**,  
235/02, 401/04, 401/14, 403/04, 403/14, 405/14, 409/14,  
471/04, 471/14, 495/04, A61K 31/4164, 31/4178,  
31/4184, 31/4188

(74) Agent: MBM & CO.; P.O. Box 809, Station B, Ottawa,  
Ontario K1P 5P9 (CA).

(21) International Application Number:  
PCT/IB2004/052433

(22) International Filing Date:  
15 November 2004 (15.11.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/520,279 14 November 2003 (14.11.2003) US  
60/599,509 6 August 2004 (06.08.2004) US

(71) Applicant (for all designated States except US): **LORUS  
THERAPEUTICS INC.** [CA/CA]; 2 Meridian Road,  
Toronto, Ontario M9W 4Z7 (CA).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **HUESCA, Mario**  
[MX/CA]; 26 Harris Park Drive, Toronto, Ontario M1L  
3A2 (CA). **AL-QAWASMEH, Raed** [CA/CA]; 15 Vicora  
Linkway Apt. 1004, North York, Ontario M3C 1A8 (CA).  
**YOUNG, Aiping, H.** [CA/CA]; 201 Senlac Road, North  
York, Ontario M2R 1P3 (CA). **LEE, Yoon** [CA/CA]; 2219  
Corsair Road, Mississauga, Ontario L5A 2L7 (CA).

(81) Designated States (unless otherwise indicated, for every  
kind of national protection available): AE, AG, AL, AM,  
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,  
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,  
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,  
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,  
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,  
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,  
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,  
ZW.


(84) Designated States (unless otherwise indicated, for every  
kind of regional protection available): ARIPO (BW, GH,  
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,  
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,  
FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE,  
SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,  
GW, ML, MR, NE, SN, TD, TG).

**Published:**

- with international search report
- before the expiration of the time limit for amending the  
claims and to be republished in the event of receipt of  
amendments

For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.

(54) Title: **ARYL IMIDAZOLES AND THEIR USE AS ANTI-CANCER AGENTS**



(I)

(57) Abstract: Therapeutically effective 2,4,5-trisubstituted imidazole compounds are pro-  
vided. Also provided are methods of preparing the compounds and pharmaceutical compo-  
sitions comprising the compounds alone or in combination with other agents. The present  
invention further provides for the use of the compounds as anti-cancer agents; wherein: R1 is  
aryl, substituted aryl, heterocycle, substituted heterocycle, heteroaryl, substituted heteroaryl  
or amino; R2 and R3 are independently aryl, substituted aryl, heterocycle, heteroaryl, substi-  
tuted heterocycle, or substituted heteroaryl or R2 and R3 when taken together along with the

carbon atoms they are attached to, form aryl or substituted aryl, and R4 is hydrogen, halogen, hydroxyl, thiol, lower alkyl, substituted  
lower alkyl, lower alkenyl, substituted lower alkenyl, lower alkynyl, substituted lower alkynyl, alkylalkenyl, alkyl alkynyl, alkoxy,  
alkylthio, aryl, aryloxy, amino, amido, carboxyl, aryl, substituted aryl, heterocycle, heteroaryl, substituted heterocycle, heteroalkyl,  
cycloalkyl, substituted cycloalkyl, alkylcycloalkyl, alkylcyclobutyl, nitro, cyano or -S(O)<sub>2</sub>R wherein R is alkyl, substituted  
alkyl, aryl, substituted aryl, heterocycle, heteroaryl, substituted heterocycle, or substituted heteroaryl.



**WO 2005/047266 A1**